GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
Clinical trials found that 77% of patients went into remission after receiving obe-cel
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
The formulation is backed by over 80 clinical trials and 200 scientific publications
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
